Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05194397 · ClinicalTrials.gov registry record · Phase 2
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
A Phase 2 study of Myelodysplastic Syndromes and Aplastic Anemia, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 3
- Study locations
NCT05194397 is a Phase 2 study of Myelodysplastic Syndromes and Aplastic Anemia that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 80 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (72% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05194397, a Phase 2 study of Myelodysplastic Syndromes and Aplastic Anemia, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 3
- Study locations
Study Summary
This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors. The primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 weeks. Key secondary outcomes are the change in muscle strength (ankle plantarflexion) from baseline to 16 weeks, the change in grip strength from baseline to 16 weeks, the change in lower extremity muscle mass from baseline to 16 weeks, the change in muscle OXPHOS capacity from baseline to 16 weeks, and the change in aerobic capacity (VO2 max) from baseline to 16 weeks.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- OTHER Exercise Intervention
- DIETARY_SUPPLEMENT Nicotinamide Riboside
Study Locations (3)
California
- City of Hope Medical Center - Duarte
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-02-23 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05194397
The ClinicalTrials.gov registry entry for NCT05194397 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (72% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05194397 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Pennsylvania, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05194397 about?
NCT05194397 is a clinical study titled "Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors". This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors. The primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 ...
What is the current status of trial NCT05194397?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2023-02-23. Estimated completion is 2026-06-30.
What conditions does trial NCT05194397 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Aplastic Anemia, Cancer Survivors, Myeloid Leukemia, Lymphoblastic Leukemia.
What interventions are being tested in trial NCT05194397?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Exercise Intervention (OTHER), Nicotinamide Riboside (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05194397?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05194397 being conducted?
This trial has 3 study locations across California, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Ascorbate in Myelodysplastic Syndrome
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.